Getinge (OTCMKTS:GNGBY) Sets New 1-Year High – What’s Next?

Getinge (OTCMKTS:GNGBY) shares hit a new 52-week high during mid-day trading on Thursday. The company traded as high as $25.9950 and last traded at $25.9950, with a volume of 249 shares changing hands. The stock had previously closed at $25.51.

Analyst Ratings Changes

GNGBY has been the subject of several research analyst reports. Nordea Equity Research cut Getinge from a “buy” rating to a “hold” rating in a research note on Monday, August 31st. UBS Group assumed coverage on shares of Getinge in a research note on Wednesday, September 2nd. They issued a “hold” rating for the company. Pareto Securities cut shares of Getinge from a “strong-buy” rating to a “hold” rating in a report on Thursday, September 24th. Finally, Zacks Research downgraded shares of Getinge from a “strong-buy” rating to a “hold” rating in a research note on Thursday, September 17th. Four investment analysts have rated the stock with a Hold rating. Based on data from MarketBeat, the company has a consensus rating of “Hold”.

Getinge Stock Up 0.8%

The firm has a market capitalization of $7.14 billion, a price-to-earnings ratio of 24.96 and a beta of 0.95. The stock has a 50 day moving average of $25.06 and a 200 day moving average of $22.59. The company has a quick ratio of 0.74, a current ratio of 1.31 and a debt-to-equity ratio of 0.26.

Getinge (OTCMKTS:GNGBY) last announced its quarterly earnings data on Friday, July 17th. The company reported $0.38 earnings per share (EPS) for the quarter. Getinge had a return on equity of 11.12% and a net margin of 7.81%. The firm had revenue of $894.87 million for the quarter. As a group, analysts expect that Getinge will post 1.38 earnings per share for the current fiscal year.

About Getinge

Getinge AB is a Swedish medical technology company that develops products and solutions for hospitals, healthcare providers and life sciences organizations. Its offerings are designed to support surgical procedures, intensive care, infection prevention and the manufacture of pharmaceuticals and other medical products.

The company’s portfolio includes operating room and surgical workflow systems, anesthesia and ventilation equipment, intensive care solutions, cardiovascular devices, sterilization and disinfection systems, and equipment for laboratories and pharmaceutical production.